Our Services

China Growth Consulting

Elite develops actionable growth strategies and market access plans for multinationals in China. For Chinese manufacturers, our growth consulting focuses on organizational effectiveness. Elite provides sales force planning and implementation for both Chinese manufacturers and multinationals.

Commercial & Regulatory Assessments

For private equity and strategic investors, Elite does commercial due diligence on over $300 million USD of direct investment each year in pharmaceuticals, devices, and medical services. For late stage venture backed product developers and mid-sized public companies, Elite does market opportunity and regulatory assessments to support market entry of new pharmaceutical, diagnostics, and medical devices.

Financial Advisory

Elite’s deep relationship to the domestic industry makes us experts in finding high-value China healthcare investments and negotiating with Chinese medical companies. Our services include growth equity capital, sell side mandate, and buy side mandate.

Regulatory & Medical Implementation

Elite provide regulatory and medical consulting and implementation services for venture backed companies and mid-sized multinationals. With thorough understanding of the regulatory process and has strong ties to healthcare institutions and governmental agencies, Elite offers a range of services, including CFDA registration, KOL mapping for clinical trial, KOL recruitment and engagement management, CFDA clinical trial protocol development, and clinical trial management.

Sales & Marketing Training

For domestic and multinational pharmaceutical and medical device companies, Elite offers sales and marketing training. Elite has performed training sessions for over 1,500 pharmaceutical and medical device companies, and more than 100,000 professionals have graduated from our training programs. Elite’s team of accomplished and highly experienced industry veterans can offer a unique blend of insights and techniques to improve your organizational performance.